Xuanzhu Biopharmaceutical (02575) Releases Monthly Return for January 2026

Bulletin Express

Feb 05

Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575) published its Monthly Return for Equity Issuer for the period ended 31 January 2026. According to the report, the total issued share capital remains at 517,947,790 shares, divided into 160,701,996 H shares (listed on the Stock Exchange of Hong Kong) and 357,245,794 unlisted shares. The H shares have a par value of RMB 1 each, with a confirmed public float requirement of 24.96%.

No movement in equity or treasury shares is reported for the month. The Monthly Return indicates that there were no repurchases, redemptions, or other changes in the Company’s share capital structure within this period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1197726114"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197726114\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197726114?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 17:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197726114","market":"us","top_or_hot":-1,"title":"Xuanzhu Biopharmaceutical (02575) Releases Monthly Return for January 2026","media":"Bulletin Express","content":"<p>Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575) published its Monthly Return for Equity Issuer for the period ended 31 January 2026. According to the report, the total issued share capital remains at 517,947,790 shares, divided into 160,701,996 H shares (listed on the Stock Exchange of Hong Kong) and 357,245,794 unlisted shares. The H shares have a par value of RMB 1 each, with a confirmed public float requirement of 24.96%.</p>\n<p>No movement in equity or treasury shares is reported for the month. The Monthly Return indicates that there were no repurchases, redemptions, or other changes in the Company’s share capital structure within this period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biopharmaceutical (02575) Releases Monthly Return for January 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biopharmaceutical (02575) Releases Monthly Return for January 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-05 17:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575) published its Monthly Return for Equity Issuer for the period ended 31 January 2026. According to the report, the total issued share capital remains at 517,947,790 shares, divided into 160,701,996 H shares (listed on the Stock Exchange of Hong Kong) and 357,245,794 unlisted shares. The H shares have a par value of RMB 1 each, with a confirmed public float requirement of 24.96%.</p>\n<p>No movement in equity or treasury shares is reported for the month. The Monthly Return indicates that there were no repurchases, redemptions, or other changes in the Company’s share capital structure within this period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1197726114","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197726114","pubTimestamp":1770283535,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575) published its Monthly Return for Equity Issuer for the period ended 31 January 2026. According to the report, the total issued share capital...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"轩竹生物制药(02575)发布2026年1月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575) published its Monthly Return for Equity Issuer for the period ended 31 January 2026. According to the report, the total issued share capital remains at 517,947,790 shares, divided into 160,701,996 H shares (listed on the Stock Exchange of Hong Kong) and 357,245,794 unlisted shares. The H shares have a par value of RMB 1 each, with a confirmed public float requirement of 24.96%.\nNo movement in equity or treasury shares is reported for the month. The Monthly Return indicates that there were no repurchases, redemptions, or other changes in the Company’s share capital structure within this period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}